GeoVax Highlights Dual Protective Potential of GEO-CM04S1 Following Presentation at the AAI Annual Meeting 2025
GEO-CM04S1 Demonstrates Robust COVID-19 and Mpox Immunogenicity in Immunocompromised Patients and Healthy Adults
ATLANTA, GA - May 8, 2025 ( NEWMEDIAWIRE ) - GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing immunotherapies and vaccines against infectious diseases and solid tumor cancers, today recapped the presentation of clinical and translational data for its next-generation multi-antigen COVID-19 vaccine candidate, GEO-CM04S1, delivered at IMMUNOLOGY2025(TM), the Annual Meeting of the American Association of Immunologists (AAI), held May 3–7, 2025, in Honolulu, Hawaii.
The presentation, titled 'Immunogenicity of Synthetic MVA-based Vaccine COH04S1 Against SARS-CoV-2 in Post-HCT/CAR-T Patients and Its Cross-Protective Potential Against Mpox' (Abstract Number: 9352), highlighted findings from an the initial segment of an ongoing Phase 2 clinical study in blood cancer patients receiving hematopoietic cell transplantation or CAR-T therapy that was conducted by investigators at City of Hope Medical Center with the next-generation multi-antigen COVID-19 vaccine COH04S1 (licensed by GeoVax as GEO-CM04S1), as well as studies with sera obtained from COH04S1-vaccinated healthy adults and non-human primates demonstrating induction of orthopox-specific and Mpox cross-reactive immune responses.
The study in blood cancer/cell transplant patients demonstrated robust, durable, and broad anti-SARS-CoV-2 immune responses following vaccination with COH04S1, including cross-reactive immunity against variants of concern such as Omicron XBB.1.5. Immune responses in healthy adult and non-human primates receiving COH04S1 were cross-reactive against Mpox virus and found comparable to those in humans receiving the currently licensed smallpox/Mpox vaccine (Jynneos). Further, sera from these vaccinated individuals were shown to protect against lung infection in susceptible mice challenged with Mpox virus.
These studies demonstrate the potential of GEO-CM04S1 to provide protection against both COVID-19 and Mpox.
'These findings underscore the differentiated potential of GEO-CM04S1 to serve dual roles as both a next-generation multi-antigen COVID-19 vaccine and a cross-protective agent against Mpox,' said Kelly T. McKee, Jr., M.D., Chief Medical Officer of GeoVax. 'The ability to stimulate strong, broad, and durable immunity, particularly in immunocompromised individuals, represents a meaningful advancement over current vaccines. The added benefit of cross-reactive immunity against Mpox is especially important in regions where this virus is endemic, such as the Democratic Republic of the Congo and surrounding areas in Africa.'
About GEO-CM04S1
GEO-CM04S1 is a next-generation multi-antigen COVID-19 vaccine designed using a synthetic Modified Vaccinia Ankara (sMVA) vector platform. The vaccine expresses both the spike (S) and nucleocapsid (N) antigens of SARS-CoV-2, offering the potential for broader and more durable immune protection across current and emerging variants. GEO-CM04S1 is licensed from City of Hope and is currently being evaluated in three Phase 2 clinical trials:
About GeoVax
GeoVax Labs, Inc. is a clinical-stage biotechnology company developing novel vaccines against infectious diseases and therapies for solid tumor cancers. The Company's lead clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine currently in three Phase 2 clinical trials, being evaluated as (1) a primary vaccine for immunocompromised patients such as those suffering from hematologic cancers and other patient populations for whom the current authorized COVID-19 vaccines are insufficient, (2) a booster vaccine in patients with chronic lymphocytic leukemia (CLL) and (3) a more robust, durable COVID-19 booster among healthy patients who previously received the mRNA vaccines. In oncology the lead clinical program is evaluating a novel oncolytic solid tumor gene-directed therapy, Gedeptin(R), having recently completed a multicenter Phase 1/2 clinical trial for advanced head and neck cancers. The Company is also developing GEO-MVA, a vaccine targeting Mpox and smallpox. GeoVax has a strong IP portfolio in support of its technologies and product candidates, holding worldwide rights for its technologies and products. For more information about the current status of our clinical trials and other updates, visit our website: www.geovax.com.
Forward-Looking Statements
This release contains forward-looking statements regarding GeoVax's business plans. The words 'believe,' 'look forward to,' 'may,' 'estimate,' 'continue,' 'anticipate,' 'intend,' 'should,' 'plan,' 'could,' 'target,' 'potential,' 'is likely,' 'will,' 'expect' and similar expressions, as they relate to us, are intended to identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy and financial needs. Actual results may differ materially from those included in these statements due to a variety of factors, including whether: GeoVax is able to obtain acceptable results from ongoing or future clinical trials of its investigational products, GeoVax's immuno-oncology products and preventative vaccines can provoke the desired responses, and those products or vaccines can be used effectively, GeoVax's viral vector technology adequately amplifies immune responses to cancer antigens, GeoVax can develop and manufacture its immuno-oncology products and preventative vaccines with the desired characteristics in a timely manner, GeoVax's immuno-oncology products and preventative vaccines will be safe for human use, GeoVax's vaccines will effectively prevent targeted infections in humans, GeoVax's immuno-oncology products and preventative vaccines will receive regulatory approvals necessary to be licensed and marketed, GeoVax raises required capital to complete development, there is development of competitive products that may be more effective or easier to use than GeoVax's products, GeoVax will be able to enter into favorable manufacturing and distribution agreements, and other factors, over which GeoVax has no control.
Further information on our risk factors is contained in our periodic reports on Form 10-Q and Form 10-K that we have filed and will file with the SEC. Any forward-looking statement made by us herein speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law.
Company Contact:
[email protected]
678-384-7220
Investor Relations Contact:
[email protected]
212-698-8696
View the original release on www.newmediawire.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
A New COVID Variant Is Here, And It's More Transmissible — Here Are The Signs And Symptoms
A new COVID variant known as NB.1.8.1 has made landfall in the United States. The variant, which was first detected in China this past January, currently accounts for 10% of the SARS-CoV-2 sequences tested from around the world, recent surveillance data found. That's a significant jump from 2.5% four weeks ago. A Centers for Disease Control and Prevention (CDC) spokesperson told HuffPost that the agency is in regular contact with international partners about the activity of NB.1.8.1. To date, only 20 NB.1.8.1 sequences have been identified in the U.S. — that's below the threshold needed for a variant to appear on the agency's COVID dashboard. (As soon as its prevalence increases, NB.1.8.1 will pop up on the tracker, the spokesperson added.) It's nerve-wracking to hear that a new variant is making the rounds, but infectious disease specialists say there are no glaring differences between the symptoms of NB.1.8.1 and those caused by other versions of SARS-CoV-2. 'Currently it appears that NB.1.8.1 would have similar symptoms to other COVID variants that have recently been circulating,' Dr. Zachary Hoy, a pediatric infectious disease specialist with Pediatrix Medical Group in Nashville, Tennessee, told HuffPost. Here's what to know about the newest COVID variant that's gaining traction around the world. Compared to the currently dominant variant in the U.S. (LP.8.1), NB.1.8.1 has a handful of new mutations on the spike protein that may enhance its ability to bind to our cells, according to the World Health Organization (WHO). The agency suspects these mutations will increase the virus's transmissibility and, potentially, diminish the effectiveness of neutralizing antibodies that prevent pathogens from latching to our cells. In other words, the variant may be skilled at dodging some of our immune defenses, research suggests. According to Dr. Amesh Adalja, an infectious diseases expert and senior scholar at the Johns Hopkins University Center for Health Security, NB.1.8.1's symptoms are pretty much the same as those seen with other SARS-CoV-2 variants. Two of COVID's hallmark symptoms are a mild but persistent dry cough and nasal congestion, Hoy said. Many people who come down with COVID are also hit with fatigue and tiredness. 'An infected person can still make it through the day, but they are resting more and feel more tired throughout the day,' Hoy said. Other common symptoms include a fever, chills, a sore throat and muscle aches. 'Some have described recent variants as less intense symptoms as compared to wintertime influenza viruses, but both can have severe symptoms,' Hoy said. There's no evidence suggesting the variant causes more severe disease or an uptick in hospitalizations or deaths, the WHO states. The only noticeable aspect, as of now, is that it's rising in prevalence, Adalja said. It's too early to know exactly how effective the shots are — as the research on NB.1.8.1 is limited since it's so new — but scientists expect the shots to hold up well. NB.1.8.1 broke off from the Omicron JN.1 lineage, which the 2024-2025 vaccines target. 'The ability of the vaccines to prevent severe illness is intact though protection versus infection is limited and transient,' Adalja said. Anyone who is at risk of severe disease should stay up-to-date with the shots. 'Those in older populations or with underlying immune disorders or on immune-decreasing medications would benefit more from vaccination or those with increased exposure such as healthcare workers,' Hoy added. So if you have a condition that puts you at risk, it's worth getting vaccinated if it's been more than six months since your last vaccine or bout of COVID, Adalja advises. He also added that those who are low-risk likely do not need to go out and get another shot. Most people will be able to recover at home by resting and staying hydrated. While you're sick, acetaminophen and ibuprofen can help alleviate muscle aches and fevers, Hoy said. And, in most cases, symptoms should clear up within a week. For those who are at risk for severe disease, including older adults and people who are immune-compromised, it's worth contacting a physician as they can prescribe antivirals — Paxlovid and Molnupiravir — that can significantly lower the risk of severe complications and death. As was the case with previous variants, these antivirals work best when started within five days of symptom onset. As for when you should go to an urgent care or emergency room? When you have chest pain, have a hard time waking up or staying awake, or feel confused and disoriented, the CDC advises. Hoy says the most concerning symptom he warns patients about is difficulty breathing. 'If you have COVID or COVID-like illness and have worsening trouble breathing or chest pain, you should be evaluated at your doctor's office, urgent care or the ER,' he said. RFK Jr. Says COVID Shot Will No Longer Be Advised For Healthy Kids, Pregnant Women Trump's FDA Has Axed COVID Boosters For Most People — And Medical Experts Are Deeply Worried New Trump Vaccine Policy Limits Access To COVID Shots
CNBC
2 hours ago
- CNBC
Why Disney and Universal are investing billions into their theme parks
The Walt Disney Company and Universal, two of the biggest names in theme parks, are both undertaking historic expansions to their experiences businesses. Universal Orlando Resort in May opened the gates to Epic Universe, its fourth theme park at its flagship resort. Epic cost an estimated $7 billion to build, according to numbers provided by the University of Central Florida. Brian Roberts, Chairman and CEO of Universal parent company Comcast, called it the "single-largest investment Comcast NBCUniversal has made in its theme park business". "It's so different than anything else that we've ever built, but certainly I think it's different than anything anyone's ever built," said Karen Irwin, Universal Orlando President and COO. Epic's opening coincides with an expansion of Universal Orlando's resort portfolio, adding three Loews hotels to bring its total to 11 operated on the property. Universal is betting that the addition of Epic will turn the resort into a full-week destination, a distinction that is normally reserved for its crosstown neighbor, Walt Disney World. Not to be upstaged, Disney is working on a historic undertaking of its own. In 2023, Disney announced plans to invest $60 billion in its experiences segment, which includes theme parks, cruise ships and consumer products. Of that investment, $30 billion will go to its domestic theme parks, Disney World and Disneyland. "We've got a lion's share of that investment coming to us," said Michael Hundgen, portfolio executive creative producer with Walt Disney Imagineering. "It's about finding what strikes the best creative intent in the most value oriented way possible." These investments come at a time when both Disney and Comcast are paring down or spinning off their linear TV segments, an arena that has seen volatility in recent years. By comparison, theme parks have been consistent revenue drivers for the companies in the post-COVID tourism bounce. However, the timing of these openings and expansions could prove challenging for both theme parks. Epic's opening summer coincides with fears of a travel slowdown due to economic volatility. "If you're uncertain how the economy is going to develop, then you're going to try to be more cautious in your spending," said Jorge Ridderstaat, associate professor at UCF's Rosen College of Hospitality Management.
CNBC
2 hours ago
- CNBC
Trump wants to bring manufacturing jobs back. The aviation industry can't hire fast enough
LAFAYETTE, Ind. — President Donald Trump has said he wants to bolster manufacturing jobs and other technical employment in the United States. But in the aviation industry, finding skilled workers to make airplanes and engines — and maintaining those jobs for years to come — has been a struggle. The average age of a certified aircraft mechanic in the U.S. is 54, and 40% of them are over the age of 60, according to a joint 2024 report from the Aviation Technician Education Council and consulting firm Oliver Wyman, which cites Federal Aviation Administration data. The U.S. will be short 25,000 aircraft technicians by 2028, according to the report. "A lot of them were hired on in the '80s and early '90s. You just start doing some math and you start saying at some point they're going to retire," said American Airlines Chief Operating Officer David Seymour, who oversees the carrier's more than 6,000 daily flights. To boost their ranks, airlines and big manufacturers of airplanes and their thousands of components are trying to get more younger people interested in the field. The industry was already facing a retirement wave when Covid hit, and companies cut or offered buyouts to experienced workers — from those who build aircraft to those who maintain them to keep flying. "People forget that the aerospace industry was in a pretty serious ramp at the time pre-Covid. And then frankly, of course overnight we went from ramping to zero demand over time. And so we lost a lot of talent," said Christian Meisner, GE Aerospace's chief human resources officer. GE, along with its French joint venture partner Safran, makes the bestselling engines that power Boeing and Airbus top-selling jetliners, and has been ramping up hiring, though it is also dependent on a web of smaller suppliers that have also been getting back up to speed since the pandemic. Meisner said that the company has a strong retention rate and that some employees earn their FAA licenses to work on airplane engines or airframes on the job. At GE's engine plant in Lafayette, Indiana, about an hour outside of Indianapolis, base pay averages between $80,000 and $90,000 a year, based on qualifications and experience, the company said. Median pay for aircraft technicians or mechanics was $79,140 a year in the U.S. in 2024, compared with a nationwide median income of $49,500, according to the Bureau of Labor Statistics. The agency projects 13,400 job openings in the field each year over the next decade. American's Seymour said that with new pay raises, technicians could make $130,000 a year at the top of their pay scale in nine years at the carrier. While many experts don't expect jobs that have been shipped abroad like clothing manufacturing to come back to the U.S., high-value sectors tend to pay much more and are more likely to stick around. But hiring can still be difficult in a sector that is seen as politically important and symbolic to the country's economic power. The impending worker shortages aren't just for those who repair aircraft and engines. A shortfall of air traffic controllers has also stifled airline growth and raised concerns about safety in recent years. The Trump administration has said it will raise wages and ramp up hiring to try to reverse yearslong shortfalls. Manufacturing is about 9% of U.S. employment but "we all have a bit of a fetish with manufacturing because we focus on it more and than other sectors," said Gordon Hanson, a professor of urban policy at Harvard University. The U.S. unemployment rate in May held steady at 4.2%. One problem with manufacturing jobs, Hanson said, is that workers aren't very geographically mobile, and if factories reopen or hiring ramps up, that could make it harder to attract employees from other places. "You're asking the local labor market to supply workers," Hanson added. Wages for technicians that repair aircraft at airlines, as well as big manufacturers like Boeing, have gone up in recent years, with skilled workers still in short supply and travel and airplane demand robust. But some workers said that's not enough. "We need to increase wages," said Sarah MacLeod, executive director of the Aeronautical Repair Station Association. Most of the companies the association works with are small businesses. She warned that the "entire world is going to feel this workforce shortage. You already can't get your houses built. You already can't do XYZ. I think and pray that aerospace can actually lead the recovery of that." Getting FAA licenses can take years, but the reward can be high. Some students are considering forgoing traditional four-year college degrees straight out of high school to get into the industry. "I'm thinking about going to college, but it's whichever really comes first. If they give me an opportunity to go to the airlines, I'd like to do that," said Sam Mucciardi, a senior at Aviation High School in Queens, New York. The public school offers its roughly 2,000 students the option to stay on for a fifth year to earn their FAA licenses with training at the school. "I stay late after school every day to work on the planes and, probably a little bit too much ... but I still really enjoy it," Mucciardi said. "That's what I put my all my heart into." The school, which has been teaching students how to maintain aircraft since the 1930s, is fielding more demand from airlines in recent years. "After a program like ours, typically you'd go to the regional airlines first, like the Endeavors, the Envoys," said Aviation High School Principal Steven Jackson. "Lately, because of the huge technician need, there's been more students going directly into American, Delta, United, but you have the whole range." He said the school received about 5,000 applications this year from students. Students at the school learn at the campus in the Sunnyside section of Queens but also at other facilities at John F. Kennedy International Airport. Seymour said American has teamed up with high schools before, but is now going even younger and working with some junior highs to raise awareness about the career path. "It is getting into the high schools and showing that a career in aerospace as an engineer or frankly, on a production floor, is not your grandparents' manufacturing. It is high tech," GE's Meisner said. "You're talking about laser-guided machine, precision machining operations, exotic coatings and metals." Krystal Godinez, who has lived in the Lafayette area for about 14 years, graduated last summer from GE's first apprentice program class at the facility after about two years. She said she previously worked in the automotive industry. "I feel like what I do here … definitely does matter. It's like taking all those extra steps, make sure everything is correct," she said. "We're there to kind of keep people safe out there and make them feel safe." American's Seymour was optimistic that younger people are changing their tune. "There was a period of time when people said 'I want a computer, I want tech,'" he said. "There are people who want to get their hands dirty." --
